BioSpace News Archive

Helius Medical Technologies, Inc., a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced the addition the Montefiore Medical Center to its PoNS Therapeutic Experience Program.

Gain Therapeutics, Inc. announced that a late breaking abstract highlighting the company’s lead program, GT-02287, has been accepted for presentation at the upcoming International Congress of Parkinson’s Disease and Movement Disorders® to be held August 27-31, in Copenhagen, Denmark.

Krystal Biotech, Inc. reported financial results and key operational progress updates for the second quarter ended June 30, 2023.

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the second quarter ended June 30, 2023.

The acceptance of icosapent ethyl, an innovative active substance comprising a highly purified omega-3 fatty acid (eicosapentaenoic acid greater or equal to 96%), will provide healthcare professionals in Scotland with an additional treatment option to be considered for eligible patients who are at high risk of a subsequent CV event, such as a second heart attack or stroke.

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update on key events since the start of 2023.

STAAR Surgical Company today announced that management will participate in several upcoming investor conferences.

Castle Biosciences, Inc. today announced a new study published in The American Journal of Gastroenterology showing how use of TissueCypher® Barrett’s Esophagus test results can significantly improve management decisions for Barrett’s esophagus (BE) patients with low-grade dysplasia (LGD) to improve health outcomes.

Tabula Rasa HealthCare, Inc.® today reported financial results for the second quarter ended June 30, 2023.

Envista Holdings Corporation announced its intention to offer, subject to market and other conditions, $435,000,000 in aggregate principal amount of Convertible Senior Notes due 2028 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.